Legal & General Group
ABOS icon

Legal & General Group’s Acumen Pharmaceuticals ABOS Stock Holding History

Legal & General Group’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,635
Closed -$4K – 3417
2025
Q1 		$4K Hold
3,635
– – ﹤0.01% 3308
2024
Q4 		$6.25K Hold
3,635
– – ﹤0.01% 3323
2024
Q3 		$9.02K Hold
3,635
– – ﹤0.01% 3290
2024
Q2 		$8.8K Buy
+3,635
New +$11.6K ﹤0.01% 3323
2022
Q2 		– Sell
-2,762
Closed -$11K – 3512
2022
Q1 		$11K Buy
2,762
+1,874
+211% +$10.2K ﹤0.01% 3377
2021
Q4 		$6K Hold
888
– – ﹤0.01% 3530
2021
Q3 		$13K Buy
+888
New +$14.8K ﹤0.01% 3393

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Legal & General Group's ABOS Position: Q2 2025 in Review

Legal & General Group sold out of Acumen Pharmaceuticals (ABOS) in Q2 2025, closing a stake of 3,635 shares — an estimated $4K sold.

Legal & General Group first reported a position in ABOS in Q3 2021 and held it in 7 quarters. The position peaked at $13K in Q3 2021. 71 funds tracked by Wall St. Rank hold ABOS as of Q2 2025.

  • Legal & General Group reported no remaining Acumen Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 3,635 Acumen Pharmaceuticals shares in Q2 2025, an estimated $4K.
  • Legal & General Group first reported a position in Acumen Pharmaceuticals in Q3 2021 and held it in 7 quarters.
  • Legal & General Group's Acumen Pharmaceuticals position peaked at $13K in Q3 2021.
  • 71 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.